NO312813B1 - Anvendelse av N-(2,6-dimetylfenyl)-2-(2-okso-1- pyrrolidinyl)acetamid - Google Patents
Anvendelse av N-(2,6-dimetylfenyl)-2-(2-okso-1- pyrrolidinyl)acetamid Download PDFInfo
- Publication number
- NO312813B1 NO312813B1 NO19921724A NO921724A NO312813B1 NO 312813 B1 NO312813 B1 NO 312813B1 NO 19921724 A NO19921724 A NO 19921724A NO 921724 A NO921724 A NO 921724A NO 312813 B1 NO312813 B1 NO 312813B1
- Authority
- NO
- Norway
- Prior art keywords
- dementia
- disturbances
- symptoms
- compound
- dimethylphenyl
- Prior art date
Links
- NGHTXZCKLWZPGK-UHFFFAOYSA-N nefiracetam Chemical compound CC1=CC=CC(C)=C1NC(=O)CN1C(=O)CCC1 NGHTXZCKLWZPGK-UHFFFAOYSA-N 0.000 title claims abstract description 5
- 206010012289 Dementia Diseases 0.000 claims abstract description 23
- 208000024891 symptom Diseases 0.000 claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 14
- 208000013677 cerebrovascular dementia Diseases 0.000 claims abstract description 11
- 230000003340 mental effect Effects 0.000 claims abstract description 11
- 230000006870 function Effects 0.000 claims abstract description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 6
- 206010000117 Abnormal behaviour Diseases 0.000 claims abstract description 5
- 230000004970 emotional disturbance Effects 0.000 claims abstract description 5
- 150000003839 salts Chemical class 0.000 claims abstract description 4
- 230000007423 decrease Effects 0.000 claims abstract description 3
- 230000008450 motivation Effects 0.000 claims abstract description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 229940126062 Compound A Drugs 0.000 description 22
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 230000007012 clinical effect Effects 0.000 description 3
- 239000002664 nootropic agent Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000002595 magnetic resonance imaging Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000001777 nootropic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000024823 antisocial personality disease Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Materials For Medical Uses (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP22981991 | 1991-05-02 | ||
| JP22981891 | 1991-05-02 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO921724D0 NO921724D0 (no) | 1992-04-30 |
| NO921724L NO921724L (no) | 1992-11-03 |
| NO312813B1 true NO312813B1 (no) | 2002-07-08 |
Family
ID=26529012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19921724A NO312813B1 (no) | 1991-05-02 | 1992-04-30 | Anvendelse av N-(2,6-dimetylfenyl)-2-(2-okso-1- pyrrolidinyl)acetamid |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US5886023A (pt) |
| EP (1) | EP0515866B1 (pt) |
| KR (1) | KR100310590B1 (pt) |
| AT (1) | ATE203402T1 (pt) |
| AU (2) | AU1595492A (pt) |
| CA (1) | CA2067614C (pt) |
| CZ (1) | CZ281170B6 (pt) |
| DE (1) | DE69231955T2 (pt) |
| DK (1) | DK0515866T3 (pt) |
| ES (1) | ES2160097T3 (pt) |
| GR (1) | GR3036970T3 (pt) |
| HK (1) | HK1002153A1 (pt) |
| HU (1) | HU224689B1 (pt) |
| IE (1) | IE921377A1 (pt) |
| IL (1) | IL101738A (pt) |
| MX (1) | MX9202058A (pt) |
| NO (1) | NO312813B1 (pt) |
| PT (1) | PT515866E (pt) |
| RU (1) | RU2070042C1 (pt) |
| SG (1) | SG49650A1 (pt) |
| SK (1) | SK279285B6 (pt) |
| TW (1) | TW199096B (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20000048847A (ko) | 1996-10-01 | 2000-07-25 | 스즈키 다다시 | 미토콘드리아 막 안정화제 |
| DE69823851D1 (de) | 1997-07-15 | 2004-06-17 | Daiichi Seiyaku Co | Nefiracetam zur prophylaxe und behandlung von propofol verursachtem gedächtnisschwund |
| US20040077709A1 (en) * | 1999-05-31 | 2004-04-22 | Daiichi Pharmaceutical Co., Ltd. | Neuronal death inhibitors |
| WO2000072844A1 (fr) * | 1999-05-31 | 2000-12-07 | Daiichi Pharmaceutical Co., Ltd. | Inhibiteurs de la mort neuronale |
| US6376489B1 (en) * | 1999-12-23 | 2002-04-23 | Icos Corporation | Cyclic AMP-specific phosphodiesterase inhibitors |
| GB0004297D0 (en) * | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US6423739B1 (en) | 2000-02-23 | 2002-07-23 | Daiichi Pharmaceutical Co., Ltd. | Method for aiding cerebral recovery following neurodegeneration |
| US6348489B1 (en) * | 2000-04-11 | 2002-02-19 | Daiichi Pharmaceutical Co., Ltd. | Method of treating traumatic brain injury and other neuronal disorders |
| KR100823668B1 (ko) * | 2000-12-28 | 2008-04-21 | 해밀턴 파마슈티컬스 인코포레이티드 | 신경성 통증 치료 및 예방약 |
| ATE404192T1 (de) * | 2001-08-22 | 2008-08-15 | Hamilton Pharmaceuticals Inc | Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration |
| US20060241144A1 (en) * | 2005-04-20 | 2006-10-26 | Albert Cha | Method for treating apathy syndrome |
| US7972633B2 (en) * | 2007-02-07 | 2011-07-05 | Applied Cognitive Sciences, LLC | Nutritional supplements for healthy memory and mental function |
| EP2346500B1 (en) * | 2008-10-16 | 2017-05-17 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| WO2011100373A1 (en) * | 2010-02-09 | 2011-08-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| EP3827820A1 (en) | 2013-03-15 | 2021-06-02 | The Johns Hopkins University | Brivaracetam for improving cognitive function |
| JP6433482B2 (ja) | 2013-03-15 | 2018-12-05 | エージンバイオ， インコーポレイテッド | 認知機能を改善するための方法および組成物 |
| WO2016191288A1 (en) | 2015-05-22 | 2016-12-01 | Agenebio, Inc. | Extended release pharmaceutical compositions of levetiracetam |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE864269A (fr) * | 1977-03-03 | 1978-06-16 | Parke Davis & Co | Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire |
| IT1141287B (it) * | 1979-06-13 | 1986-10-01 | Nattermann A & Cie | Ammidi di acidi pirrolidin-(2)-on-(1)-ilalchil-carbossilici,procedimento per la loro preparazione e prodotti medicinali che le contengono |
| US4385053A (en) * | 1981-03-11 | 1983-05-24 | Barry Reisberg | Treatment for human memory impairment associated with aging |
| JPH0699307B2 (ja) * | 1987-08-20 | 1994-12-07 | キッセイ薬品工業株式会社 | 抗痴呆剤 |
| IT1231477B (it) * | 1989-07-12 | 1991-12-07 | Sigma Tau Ind Farmaceuti | (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti |
-
1992
- 1992-04-29 SK SK1306-92A patent/SK279285B6/sk unknown
- 1992-04-29 CA CA002067614A patent/CA2067614C/en not_active Expired - Lifetime
- 1992-04-29 CZ CS921306A patent/CZ281170B6/cs not_active IP Right Cessation
- 1992-04-30 EP EP92107421A patent/EP0515866B1/en not_active Expired - Lifetime
- 1992-04-30 ES ES92107421T patent/ES2160097T3/es not_active Expired - Lifetime
- 1992-04-30 RU SU5011760/14A patent/RU2070042C1/ru not_active IP Right Cessation
- 1992-04-30 HU HU9201477A patent/HU224689B1/hu not_active IP Right Cessation
- 1992-04-30 MX MX9202058A patent/MX9202058A/es not_active IP Right Cessation
- 1992-04-30 PT PT92107421T patent/PT515866E/pt unknown
- 1992-04-30 AT AT92107421T patent/ATE203402T1/de not_active IP Right Cessation
- 1992-04-30 SG SG1996002798A patent/SG49650A1/en unknown
- 1992-04-30 IL IL10173892A patent/IL101738A/en active IP Right Grant
- 1992-04-30 DK DK92107421T patent/DK0515866T3/da active
- 1992-04-30 NO NO19921724A patent/NO312813B1/no unknown
- 1992-04-30 DE DE69231955T patent/DE69231955T2/de not_active Expired - Lifetime
- 1992-05-01 AU AU15954/92A patent/AU1595492A/en not_active Abandoned
- 1992-05-01 TW TW081103420A patent/TW199096B/zh active
- 1992-05-01 KR KR1019920007433A patent/KR100310590B1/ko not_active IP Right Cessation
- 1992-07-01 IE IE137792A patent/IE921377A1/en not_active IP Right Cessation
-
1995
- 1995-05-22 US US08/447,054 patent/US5886023A/en not_active Expired - Fee Related
- 1995-11-08 AU AU37745/95A patent/AU697936B2/en not_active Ceased
-
1998
- 1998-01-21 HK HK98100554A patent/HK1002153A1/xx not_active IP Right Cessation
-
2001
- 2001-10-22 GR GR20010401840T patent/GR3036970T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69231955D1 (de) | 2001-08-30 |
| GR3036970T3 (en) | 2002-01-31 |
| RU2070042C1 (ru) | 1996-12-10 |
| HUT62790A (en) | 1993-06-28 |
| SK279285B6 (sk) | 1998-09-09 |
| HK1002153A1 (en) | 1998-07-31 |
| NO921724D0 (no) | 1992-04-30 |
| CZ281170B6 (cs) | 1996-07-17 |
| ES2160097T3 (es) | 2001-11-01 |
| EP0515866A1 (en) | 1992-12-02 |
| DE69231955T2 (de) | 2002-04-04 |
| CS130692A3 (en) | 1992-11-18 |
| US5886023A (en) | 1999-03-23 |
| MX9202058A (es) | 1993-03-01 |
| AU1595492A (en) | 1992-11-05 |
| HU9201477D0 (en) | 1992-07-28 |
| KR920021143A (ko) | 1992-12-18 |
| PT515866E (pt) | 2001-11-30 |
| AU697936B2 (en) | 1998-10-22 |
| IE921377A1 (en) | 1992-11-04 |
| CA2067614A1 (en) | 1992-11-03 |
| DK0515866T3 (da) | 2001-09-24 |
| TW199096B (pt) | 1993-02-01 |
| AU3774595A (en) | 1996-03-07 |
| KR100310590B1 (ko) | 2001-12-28 |
| ATE203402T1 (de) | 2001-08-15 |
| IL101738A (en) | 1999-01-26 |
| EP0515866B1 (en) | 2001-07-25 |
| NO921724L (no) | 1992-11-03 |
| HU224689B1 (hu) | 2005-12-28 |
| CA2067614C (en) | 2002-07-30 |
| IL101738A0 (en) | 1992-12-30 |
| SG49650A1 (en) | 1998-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO312813B1 (no) | Anvendelse av N-(2,6-dimetylfenyl)-2-(2-okso-1- pyrrolidinyl)acetamid | |
| US20200113882A1 (en) | Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions | |
| IE83506B1 (en) | Use of N-(2,6-dimethylphenyl)-2-(2-oxo-1- pyrrolidinyl)acetamide for the treatment of dementia | |
| US20200113883A1 (en) | Durable treatment with 4-aminopyridine in patients with demyelination | |
| DE69621799T2 (de) | Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen | |
| DE3811274A1 (de) | Neue anwendungen von dopamin rezeptor-agonisten | |
| JPH05194209A (ja) | 血管内皮細胞機能改善剤 | |
| Akanuma et al. | Long-term comparison of oral hypoglycemic agents in diabetic retinopathy Gliclazide vs. other sulfonylureas | |
| US20190224208A1 (en) | Pharmaceutical composition for treating premature ejaculation and method for treating premature ejaculation | |
| JPH02212421A (ja) | 痴呆治療剤 | |
| DE69200365T2 (de) | Pharmazeutische Zusammensetzung zur Verbesserung von Dysuria. | |
| JP3388777B2 (ja) | アルツハイマー型痴呆改善剤 | |
| JP3388778B2 (ja) | 脳血管性痴呆改善剤 | |
| EP1698622B1 (en) | Treatment for severe aphasia in chronic-stage cerebrovascular disorder | |
| US7479506B2 (en) | Agent or method for treating severe aphasia in cerebrovascular accident chronic stage |